IKT
Inhibikase Therapeutics, Inc.
Next earnings Aug 12, 2026 · consensus $-0.11 EPS
Last earnings -5.4% on 2026-05-12
$1.87▲ +12.65%
over 1Y
L $1.41EODHDH $2.14
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+2.2%
1M+10.0%
3M+14.7%
YTD-4.1%
1Y+12.7%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.05x); but revenue fell -100.0% YoY.
Inhibikase Therapeutics, Inc. shows $0.00 in FY2024 revenue (-100.0% YoY), and -27.9% ROE.
Sources: SEC EDGAR (CIK 0001750149, latest 10-Q filed 2026-05-12) · as of 6/26/2026, 6:34:01 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.